Profiling of cardio-metabolic risk factors and medication utilisation among Type II diabetes patients in Ghana: a prospective cohort study.

Citation data:

Clinical and translational medicine, ISSN: 2001-1326, Vol: 6, Issue: 1, Page: 32

Publication Year:
2017
Usage 24
Downloads 12
Abstract Views 12
Captures 16
Readers 15
Exports-Saves 1
Citations 1
Citation Indexes 1
Repository URL:
http://ro.ecu.edu.au/ecuworkspost2013/3364
PMID:
28879491
DOI:
10.1186/s40169-017-0162-5
Author(s):
Adua, Eric; Roberts, Peter; Sakyi, Samuel Asamoah; Yeboah, Francis Agyemang; Dompreh, Albert; Frimpong, Kwasi; Anto, Enoch Odame; Wang, Wei
Publisher(s):
Springer Nature; Springer
Tags:
Type II diabetes mellitus; Hypertension; Anti-diabetic medications; Risk factors; Ghana; Medicine and Health Sciences
article description
Type II diabetes mellitus (T2DM) is complicated by multiple cardio-metabolic risk factors. Controlling these factors requires lifestyle modifications alongside utilisation of anti-diabetic medications. Different glucose lowering [(biguanides (BIGs), sulfonylureas (SUAs), thiazolidinediones (TNZ)], lipid lowering (statins), and anti-hypertensive medicines [angiotensin converting enzyme inhibitors (ACEIs), calcium channel blockers (CCBs), angiotensin II receptor blockers (ARBs) and central acting drugs (CADs)] have been approved for controlling hyperglycaemia, dyslipidaemia and hypertension respectively. Here, we examined factors that characterise T2DM and explored the response to medication therapy among T2DM patients.